Wave Life Sciences (WVE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

WVE Stock Forecast

Wave Life Sciences stock forecast is as follows: an average price target of $22.14 (represents a 61.96% upside from WVE’s last price of $13.67) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

WVE Price Target

The average price target for Wave Life Sciences (WVE) is $22.14 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $15.00. This represents a potential 61.96% upside from WVE's last price of $13.67.

WVE Analyst Ratings

Buy

According to 7 Wall Street analysts, Wave Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for WVE stock is 1 'Strong Buy' (14.29%), 5 'Buy' (71.43%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Wave Life Sciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 12, 2024	Joon Leen	Truist Financial	$36.00	$13.49	166.86%	163.35%
Oct 21, 2024	Luca Issi	RBC Capital	$15.00	$14.80	1.35%	9.73%
Oct 17, 2024	Tiago Fauth	Wells Fargo	$22.00	$14.90	47.65%	60.94%
Oct 16, 2024	Strong Buy	Raymond James	$22.00	$14.81	48.55%	60.94%
Oct 16, 2024	Joseph Schwartz	Leerink Partners	$22.00	$15.05	46.18%	60.94%
Oct 03, 2024	Madison El-Saadi	B.Riley Financial	$19.00	$8.65	119.65%	38.99%
Sep 25, 2024	Salim Syed	Mizuho Securities	$19.00	$8.19	131.99%	38.99%
Sep 25, 2024	Madison El-Saadi	B.Riley Financial	$11.00	$8.19	34.31%	-19.53%
Jun 25, 2024	Joon Leen	Truist Financial	$17.00	$4.77	256.39%	24.36%
May 15, 2024	Tiago Fauth	Wells Fargo	$11.00	$5.84	88.36%	-19.53%

Row per page

Go to

The latest Wave Life Sciences stock forecast, released on Nov 12, 2024 by Joon Leen from Truist Financial, set a price target of $36.00, which represents a 166.86% increase from the stock price at the time of the forecast ($13.49), and a 163.35% increase from WVE last price ($13.67).

Wave Life Sciences Price Target by Period

	1M	3M	12M
# Anlaysts	2	8	10
Avg Price Target	$25.50	$20.75	$19.40
Last Closing Price	$13.67	$13.67	$13.67
Upside/Downside	86.54%	51.79%	41.92%

In the current month, the average price target of Wave Life Sciences stock is $25.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 86.54% increase as opposed to Wave Life Sciences's last price of $13.67. This month's average price target is up 22.89% compared to last quarter, and up 31.44% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 21, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Oct 17, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 17, 2024	Wells Fargo	Overweight	Overweight	Hold
Oct 16, 2024	Raymond James	Outperform	Strong Buy	Upgrade
Oct 03, 2024	B. Riley	Buy	Buy	Hold
Sep 24, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 18, 2024	B. Riley	-	Buy	Initialise
Aug 14, 2024	William Blair	-	Outperform	Initialise
Aug 09, 2024	Wells Fargo	Buy	Buy	Hold
Jun 26, 2024	Mizuho Securities	Underperform	Underperform	Hold

Row per page

Go to

Wave Life Sciences's last stock rating was published by RBC Capital on Oct 21, 2024. The company gave WVE a "Sector Perform" rating, the same as its previous rate.

Wave Life Sciences Financial Forecast

Wave Life Sciences Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$49.21M	$22.11M	$12.93M	$1.24M	$285.00K	$375.00K	$1.75M	$1.76M	$36.42M	$2.78M	-	$9.44M	$3.45M	$3.03M	$4.16M	$2.40M	$2.93M	$7.63M	$3.03M	$1.42M	$676.00K
Avg Forecast	$24.82M	$21.80M	$17.40M	$12.80M	$27.54M	$16.61M	$19.45M	$25.00M	$19.86M	$23.43M	$7.94M	$32.33M	$7.06M	$8.20M	$3.83M	$3.86M	$15.79M	$10.36M	$9.79M	$10.08M	$9.75M	$12.63M	$6.37M	$5.90M	$5.31M	$5.79M	$15.76M	$9.66M	$948.00K	$584.85K
High Forecast	$50.61M	$44.45M	$35.48M	$15.67M	$70.73M	$17.20M	$19.45M	$50.99M	$40.07M	$23.43M	$16.19M	$65.94M	$14.39M	$8.20M	$3.83M	$3.86M	$15.79M	$10.36M	$9.79M	$10.08M	$9.75M	$12.63M	$6.37M	$5.90M	$5.31M	$5.79M	$15.76M	$9.66M	$1.14M	$701.82K
Low Forecast	$5.47M	$4.81M	$3.84M	$7.84M	$1.78M	$16.02M	$19.45M	$5.51M	$213.14K	$23.43M	$1.75M	$7.13M	$1.56M	$8.20M	$3.83M	$3.86M	$15.79M	$10.36M	$9.79M	$10.08M	$9.75M	$12.63M	$6.37M	$5.90M	$5.31M	$5.79M	$15.76M	$9.66M	$758.40K	$467.88K
# Analysts	1	1	1	4	7	3	2	2	5	2	2	2	1	3	3	3	4	4	4	4	9	9	9	9	8	8	8	8	10	11
Surprise %	-	-	-	-	-	-	-	-	-	2.10%	2.79%	0.40%	0.18%	0.03%	0.10%	0.45%	0.11%	3.52%	0.28%	-	0.97%	0.27%	0.48%	0.70%	0.45%	0.51%	0.48%	0.31%	1.50%	1.16%

Wave Life Sciences's average Quarter revenue forecast for Dec 23 based on 5 analysts is $19.86M, with a low forecast of $213.14K, and a high forecast of $40.07M. WVE's average Quarter revenue forecast represents a -59.64% decrease compared to the company's last Quarter revenue of $49.21M (Sep 23).

Wave Life Sciences EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	4	7	3	2	2	5	2	2	2	1	3	3	3	4	4	4	4	9	9	9	9	8	8	8	8	10	11
EBITDA	-	-	-	-	-	-	-	-	-	$4.44M	$-23.47M	$-29.72M	$-43.56M	$-36.89M	$-39.78M	$-35.61M	$-32.45M	$-3.83M	$-36.33M	$-40.00M	$-27.12M	$-30.59M	$-38.05M	$-45.01M	$-54.34M	$-48.37M	$-39.69M	$-42.04M	$-33.89M	$-19.38M
Avg Forecast	$-22.43M	$-19.70M	$-15.72M	$-11.57M	$-24.89M	$-15.01M	$-17.58M	$-22.59M	$-17.95M	$-21.18M	$-7.17M	$-29.22M	$-6.38M	$-7.41M	$-3.46M	$-3.49M	$-14.27M	$-9.36M	$-8.84M	$-24.47M	$-8.81M	$-11.41M	$-5.75M	$-38.26M	$-4.80M	$-5.23M	$-14.25M	$-33.48M	$-18.64M	$-16.36M
High Forecast	$-4.95M	$-4.34M	$-3.47M	$-7.08M	$-1.61M	$-14.48M	$-17.58M	$-4.98M	$-192.63K	$-21.18M	$-1.58M	$-6.44M	$-1.41M	$-7.41M	$-3.46M	$-3.49M	$-14.27M	$-9.36M	$-8.84M	$-19.58M	$-8.81M	$-11.41M	$-5.75M	$-30.61M	$-4.80M	$-5.23M	$-14.25M	$-26.78M	$-14.91M	$-13.09M
Low Forecast	$-45.74M	$-40.18M	$-32.07M	$-14.17M	$-63.92M	$-15.54M	$-17.58M	$-46.08M	$-36.21M	$-21.18M	$-14.63M	$-59.60M	$-13.00M	$-7.41M	$-3.46M	$-3.49M	$-14.27M	$-9.36M	$-8.84M	$-29.37M	$-8.81M	$-11.41M	$-5.75M	$-45.91M	$-4.80M	$-5.23M	$-14.25M	$-40.18M	$-22.37M	$-19.63M
Surprise %	-	-	-	-	-	-	-	-	-	-0.21%	3.27%	1.02%	6.83%	4.98%	11.48%	10.21%	2.27%	0.41%	4.11%	1.63%	3.08%	2.68%	6.61%	1.18%	11.33%	9.25%	2.79%	1.26%	1.82%	1.18%

5 analysts predict WVE's average Quarter EBITDA for Dec 23 to be $-17.95M, with a high of $-192.63K and a low of $-36.21M. This is -503.98% lower than Wave Life Sciences's previous annual EBITDA (Sep 23) of $4.44M.

Wave Life Sciences Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	4	7	3	2	2	5	2	2	2	1	3	3	3	4	4	4	4	9	9	9	9	8	8	8	8	10	11
Net Income	-	-	-	-	-	-	-	-	-	$7.25M	$-21.10M	$-24.52M	$-43.71M	$-39.11M	$124.00K	$-37.53M	$-34.78M	$-6.23M	$-38.77M	$-42.46M	$-28.79M	$-33.10M	$-40.53M	$-47.49M	$-56.77M	$-50.73M	$-41.94M	$-44.20M	$-35.24M	$-21.00M
Avg Forecast	$-38.66M	$-33.80M	$-36.90M	$-39.11M	$-25.19M	$-37.49M	$-27.50M	$-24.66M	$-30.05M	$-23.64M	$-43.94M	$-5.30M	$-54.35M	$-64.33M	$-66.28M	$-70.13M	$-67.72M	$-77.90M	$-79.75M	$-25.33M	$-77.39M	$-89.93M	$-129.74M	$-40.37M	$-188.55M	$-176.90M	$-146.37M	$-35.20M	$-19.38M	$-17.72M
High Forecast	$517.40K	$452.35K	$493.74K	$-32.36M	$13.99M	$501.65K	$367.94K	$329.95K	$3.16M	$316.34K	$587.93K	$70.96K	$727.31K	$-64.33M	$-66.28M	$-70.13M	$-67.72M	$-77.90M	$-79.75M	$-20.27M	$-77.39M	$-89.93M	$-129.74M	$-32.30M	$-188.55M	$-176.90M	$-146.37M	$-28.16M	$-15.51M	$-14.18M
Low Forecast	$-90.91M	$-79.48M	$-86.75M	$-56.64M	$-55.97M	$-88.14M	$-64.65M	$-57.97M	$-68.00M	$-55.58M	$-103.30M	$-12.47M	$-127.79M	$-64.33M	$-66.28M	$-70.13M	$-67.72M	$-77.90M	$-79.75M	$-30.40M	$-77.39M	$-89.93M	$-129.74M	$-48.44M	$-188.55M	$-176.90M	$-146.37M	$-42.24M	$-23.26M	$-21.27M
Surprise %	-	-	-	-	-	-	-	-	-	-0.31%	0.48%	4.63%	0.80%	0.61%	-0.00%	0.54%	0.51%	0.08%	0.49%	1.68%	0.37%	0.37%	0.31%	1.18%	0.30%	0.29%	0.29%	1.26%	1.82%	1.18%

Wave Life Sciences's average Quarter net income forecast for Dec 23 is $-30.05M, with a range of $-68.00M to $3.16M. WVE's average Quarter net income forecast represents a -514.34% decrease compared to the company's last Quarter net income of $7.25M (Sep 23).

Wave Life Sciences SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	4	7	3	2	2	5	2	2	2	1	3	3	3	4	4	4	4	9	9	9	9	8	8	8	8	10	11
SG&A	-	-	-	-	-	-	-	-	-	$13.13M	$12.27M	$12.23M	$13.72M	$11.61M	$12.81M	$12.37M	$12.11M	$12.94M	$10.97M	$10.08M	$9.72M	$9.59M	$10.21M	$13.00M	$13.80M	$12.52M	$11.64M	$10.90M	$8.00M	$5.85M
Avg Forecast	$102.23M	$89.79M	$71.66M	$52.72M	$113.42M	$68.41M	$80.13M	$102.98M	$81.83M	$96.52M	$32.70M	$133.19M	$29.06M	$33.64M	$15.73M	$15.83M	$64.77M	$42.49M	$40.15M	$6.01M	$40.01M	$51.81M	$26.12M	$24.22M	$21.78M	$23.75M	$64.68M	$8.68M	$3.89M	$2.40M
High Forecast	$208.49M	$183.12M	$146.15M	$64.56M	$291.34M	$70.83M	$80.13M	$210.02M	$165.06M	$96.52M	$66.68M	$271.63M	$59.27M	$33.64M	$15.73M	$15.83M	$64.77M	$42.49M	$40.15M	$7.22M	$40.01M	$51.81M	$26.12M	$24.22M	$21.78M	$23.75M	$64.68M	$10.42M	$4.67M	$2.88M
Low Forecast	$22.54M	$19.80M	$15.80M	$32.28M	$7.35M	$65.99M	$80.13M	$22.70M	$877.95K	$96.52M	$7.21M	$29.36M	$6.41M	$33.64M	$15.73M	$15.83M	$64.77M	$42.49M	$40.15M	$4.81M	$40.01M	$51.81M	$26.12M	$24.22M	$21.78M	$23.75M	$64.68M	$6.95M	$3.11M	$1.92M
Surprise %	-	-	-	-	-	-	-	-	-	0.14%	0.38%	0.09%	0.47%	0.35%	0.81%	0.78%	0.19%	0.30%	0.27%	1.68%	0.24%	0.19%	0.39%	0.54%	0.63%	0.53%	0.18%	1.26%	2.06%	2.44%

Wave Life Sciences's average Quarter SG&A projection for Dec 23 is $81.83M, based on 5 Wall Street analysts, with a range of $877.95K to $165.06M. The forecast indicates a 523.29% rise compared to WVE last annual SG&A of $13.13M (Sep 23).

Wave Life Sciences EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	4	7	3	2	2	5	2	2	2	1	3	3	3	4	4	4	4	9	9	9	9	8	8	8	8	10	11
EPS	-	-	-	-	-	-	-	-	-	$0.07	$-0.00	$-0.24	$-0.47	$-0.42	-	$-0.62	$-0.61	$-0.12	$-0.78	$-0.86	$-0.59	$-0.86	$-1.15	$-1.38	$-1.65	$-1.48	$-1.22	$-1.36	$-1.26	$-0.89
Avg Forecast	$-0.29	$-0.26	$-0.28	$-0.29	$-0.19	$-0.28	$-0.21	$-0.19	$-0.23	$-0.18	$-0.33	$-0.04	$-0.41	$-0.50	$-0.51	$-0.54	$-0.52	$-0.60	$-0.62	$-0.59	$-0.60	$-0.69	$-1.00	$-1.25	$-1.46	$-1.37	$-1.13	$-1.19	$-0.46	$-0.65
High Forecast	-	-	-	$-0.24	$0.11	-	-	-	$0.02	-	-	-	$0.01	$-0.50	$-0.51	$-0.54	$-0.52	$-0.60	$-0.62	$-0.59	$-0.60	$-0.69	$-1.00	$-1.25	$-1.46	$-1.37	$-1.13	$-1.19	$-0.37	$-0.52
Low Forecast	$-0.69	$-0.60	$-0.65	$-0.43	$-0.42	$-0.66	$-0.49	$-0.44	$-0.51	$-0.42	$-0.78	$-0.09	$-0.96	$-0.50	$-0.51	$-0.54	$-0.52	$-0.60	$-0.62	$-0.59	$-0.60	$-0.69	$-1.00	$-1.25	$-1.46	$-1.37	$-1.13	$-1.19	$-0.55	$-0.78
Surprise %	-	-	-	-	-	-	-	-	-	-0.38%	0.00%	6.00%	1.15%	0.85%	-0.00%	1.15%	1.17%	0.20%	1.27%	1.47%	0.99%	1.24%	1.15%	1.10%	1.13%	1.08%	1.08%	1.14%	2.74%	1.37%

According to 5 Wall Street analysts, Wave Life Sciences's projected average Quarter EPS for Dec 23 is $-0.23, with a low estimate of $-0.51 and a high estimate of $0.02. This represents a -431.39% decrease compared to WVE previous annual EPS of $0.07 (Sep 23).

Wave Life Sciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
XFOR	X4 Pharmaceuticals	$0.40	$3.67	817.50%	Buy
CTMX	CytomX Therapeutics	$0.91	$5.73	529.67%	Buy
INZY	Inozyme Pharma	$3.13	$14.67	368.69%	Buy
ITOS	iTeos Therapeutics	$8.23	$37.67	357.72%	Buy
ABOS	Acumen Pharmaceuticals	$2.40	$7.00	191.67%	Buy
DAWN	Day One Biopharmaceuticals	$13.31	$38.80	191.51%	Buy
APLS	Apellis Pharmaceuticals	$26.27	$74.50	183.59%	Buy
TCRX	TScan Therapeutics	$4.41	$12.00	172.11%	Buy
ARWR	Arrowhead Pharmaceuticals	$18.57	$45.38	144.37%	Buy
TERN	Terns Pharmaceuticals	$6.17	$14.25	130.96%	Buy
ASMB	Assembly Biosciences	$16.14	$35.50	119.95%	Buy
MREO	Mereo BioPharma Group	$3.53	$6.75	91.22%	Buy
WVE	Wave Life Sciences	$13.67	$22.14	61.96%	Buy
BPMC	Blueprint Medicines	$88.69	$109.71	23.70%	Buy
AMLX	Amylyx Pharmaceuticals	$4.76	$5.33	11.97%	Buy
ALNY	Alnylam Pharmaceuticals	$235.56	$254.21	7.92%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy
PRQR	ProQR Therapeutics	$3.82	$3.63	-4.97%	Buy

WVE Forecast FAQ

Is Wave Life Sciences a good buy?

Yes, according to 7 Wall Street analysts, Wave Life Sciences (WVE) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 85.71% of WVE's total ratings.

What is WVE's price target?

Wave Life Sciences (WVE) average price target is $22.14 with a range of $15 to $36, implying a 61.96% from its last price of $13.67. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Wave Life Sciences stock go up soon?

According to Wall Street analysts' prediction for WVE stock, the company can go up by 61.96% (from the last price of $13.67 to the average price target of $22.14), up by 163.35% based on the highest stock price target, and up by 9.73% based on the lowest stock price target.

Can Wave Life Sciences stock reach $20?

WVE's average twelve months analyst stock price target of $22.14 supports the claim that Wave Life Sciences can reach $20 in the near future.

What is Wave Life Sciences's current price target trend?

2 Wall Street analysts forecast a $25.5 price target for Wave Life Sciences (WVE) this month, up 86.54% from its last price of $13.67. Compared to the last 3 and 12 months, the average price target increased by 51.79% and increased by 41.92%, respectively.

What are Wave Life Sciences's analysts' financial forecasts?

Wave Life Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $88.6M (high $158.36M, low $42.77M), average EBITDA is $-80.072M (high $-38.654M, low $-143M), average net income is $-115M (high $15.19M, low $-267M), average SG&A $364.95M (high $652.33M, low $176.18M), and average EPS is $-0.866 (high $0.115, low $-2.012). WVE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $76.81M (high $146.22M, low $21.95M), average EBITDA is $-69.419M (high $-19.838M, low $-132M), average net income is $-148M (high $-30.901M, low $-314M), average SG&A $316.4M (high $602.32M, low $90.42M), and average EPS is $-1.12 (high $-0.233, low $-2.367).

Did the WVE's actual financial results beat the analysts' financial forecasts?

Based on Wave Life Sciences's last annual report (Dec 2023), the company's revenue was $113.3M, beating the average analysts forecast of $83.57M by 35.59%. Apple's EBITDA was $-67.996M, missing the average prediction of $-75.526M by -9.97%. The company's net income was $-57.513M, missing the average estimation of $-103M by -44.12%. Apple's SG&A was $51.29M, missing the average forecast of $344.23M by -85.10%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.776 by -99.94%. In terms of the last quarterly report (Sep 2023), Wave Life Sciences's revenue was $49.21M, beating the average analysts' forecast of $23.43M by 110.03%. The company's EBITDA was $4.44M, missing the average prediction of $-21.177M by -120.98%. Wave Life Sciences's net income was $7.25M, missing the average estimation of $-23.64M by -130.68%. The company's SG&A was $13.13M, missing the average forecast of $96.52M by -86.40%. Lastly, the company's EPS was $0.0684, missing the average prediction of $-0.178 by -138.36%